The cast effectiveness of lipid lowering in Swedish primary health care

Journal of Internal Medicine

Volumn 240, Issue 1, 1996, Pages 23-29

  Johannesson, Magnus ^a   Borgquist, Lars ^b   Jönsson, Bengt ^b   Lindholm, Lars H ^b  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b NONE

Author keywords

Cholesterol; Cost effectiveness; Drug treatment; Economic evaluation; Nonpharmacological; Treatment

Indexed keywords

CHOLESTEROL; PRAVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SWEDEN; BLOOD; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; PATIENT EDUCATION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

CHOLESTEROL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HUMANS; PATIENT EDUCATION; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SWEDEN; TREATMENT OUTCOME;

EID: 0030186979     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1996.491830000.x     Document Type: Article

References (22)

1. Lindholm LH, Ekbom T, Dash C, Isacsson Å, Scherstén B, for the Cell Study Group. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies. J Intern Med 1996; 240: 13-22.
2. Lindholm LH, Ekbom T, Dash C, Ericsson M, Tibblin G, Scherstén B, for the Cell Study Group. The impact of health care given in primary care on cardiovascular risk. Br Med J 1995; 310: 1105-9.
3. Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Technology Assessment Health Care 1990; 6: 93-103.
4. Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment: a review of methodological issues. Health Policy 1991; 19: 55-78.
5. Johannesson M, Hedbrant J, Jönsson B. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inform 1991; 16: 355-62.
6. Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: an Epidemiological Investigation of Cardiovascular Disease, Section 34, Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death Using Pooled Repeated Biennial Measurements, 30 year Follow Up. Springfield: US Department of Commerce, National Technical Information Service, 1987.
7. Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: an Epidemiological Investigation of Cardiovascular Disease, Section 35, Survival Following Initial Cardiovascular Events, 30 year Follow Up. Springfield: US Department of Commerce, National Technical Information Service, 1988.
8. O'Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG et al. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Pressure 1994; 3: 404-6.
9. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke, and coronary heart disease, part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
10. Martens LL. Effect of biological and analytical variation in cholesterol mesaurement on the cost-effectiveness of cholesterol-lowering therapy. PharmacoEconomics 1992; 2: 414-21.
11. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 1990; 301: 309-14.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
13. Johannesson M, Borgquist L, Jönsson B. The costs of treating hypertension in Sweden: an empirical investigation in primary health care. Scand J Prim Health Care 1991; 9: 155-60.
14. Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of a multiple cardiovascular risk factor intervention programme in treated hypertensive men. J Intern Med 1995; 237: 19-26.
15. Johannesson M, Borgquist L, Nilsson-Ehle P, Jönsson B, Ekbom T, Lindholm LH. The cost of screening for hypercholesterolaemia: results from a clinical trial in Swedish primary health care. Scand J Clin Lab Invest 1993; 53: 725-32.
16. Gerdtham U-G, Jönsson B. The impact of aging on health care expenditures in Sweden. Health Policy 1993; 24: 1-8.
17. Thompson D, Oster G. Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature. PharmacoEconomics 1992; 2: 34-42.
18. Hay JW, Wittels EH, Gotto AM. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991; 67: 789-96.
19. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibitation for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145-51.
20. Tosteson AN, Rosenthal DI, Melton LJ, Weinstein MC. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594-603.
21. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med 1990; 112: 192-202.
22. SBU (Lindholm LH, Agenäs I, Dahlgren H, de Faire U, Hjelmdahl P, Johannesson M et al., eds.) Moderately Elevated Blood Pressure. J Intern Med 1995; 238 (Suppl. 737).